Summary
Migraine headache is thought to be associated with a dilatation of cranial blood vessels, particularly those in the dura mater, and an accompanying localized sterile inflammatory response. Sumatriptan is a highly selective 5-HT1-like receptor agonist which selectively constricts cranial blood vessels (including those in the dura mater). It also inhibits neurogenically-mediated plasma protein extravasation in the dura mater. Haemodynamic studies in anaesthetized animals have shown that sumatriptan selectively constricts the carotid arterial circulation and this effect appears to be restricted to an effect on carotid arteriovenous anastomoses. Sumatriptan has a much more selective pharmacological profile than ergot preparations which are also used in the acute treatment of migraine. The development of sumatriptan has been based on a vascular theory of migraine and its high degree of efficacy in the treatment of migraine strengthens the argument that dilatation of cranial blood vessels is the cause of vascular headache.
Similar content being viewed by others
References
Apperley E, Feniuk W, Humphrey PPA, Levy GP (1980) Evidence for two types of excitatory receptor for 5-hydroxytryptamine in dog isolated vasculature. Br J Pharmacol 68:215–224
Bom AH, Heiligers JPC Saxena PR, Verdouw PD (1989) Reduction of cephalic arteriovenous shunting by ergotamine is not mediated by 5-HT1-like or 5-HT2 receptors. Br J Pharmacol 97:383–390
Bradley PB, Engel G, Feniuk W, Fozard JR, Humphrey PPA, Middlemiss DN, Mylecharane EJ, Richardson BP, Saxena PR (1986) Proposals for the nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 25:563–576
Buzzi MG, Moskowitz MA (1990) The antimigraine drug sumatriptan (GR43175) selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 99:202–206
Connor HE, Feniuk W, Humphrey PPA (1989) Characterisation of 5-HT receptors mediating contraction of canine and primate basilar artery using GR43175 a selective 5-HT1-like receptor agonist. Br J Pharmacol 96:379–387
Conti A, Monopoli A, Forlani A, Ongini E, Antona C, Biglioli P (1990) Role of 5-HT2 receptors in serotonin-induced contraction in the human mammary artery. Eur J Pharmacol 176:207–212
Dallas FAA, Dixon CM, McCulloch RJ, Saynor DA (1989) The kinetics of14C-GR43175 in rat and dog. Cephalalgia 9 (suppl 9):53–56
Den Boer MO, Villalón CM, Heiligers JPC, Humphrey PPA, Saxena PR (1991) Role of 5-HT1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan. Br J Pharmacol (in press)
Fay T (1932) Atypical facial neuralgia, a syndrome of vascular pain. Ann Otol Rhinol Laryngol 41:1030–1062
Feniuk W, Humphrey PPA (1989) Mechanisms of 5-hydroxytryptamine-induced vasoconstriction. In: Fozard JR (ed) The peripheral actions of 5-hydroxytryptamine. Oxford University Press, Oxford, pp 100–122
Feniuk W, Humphrey PPA, Perren MJ, Watts AD (1985) A comparison of 5-hydroxytryptamine receptors mediating contraction in rabbit aorta and dog saphenous vein: evidence for different receptor types obtained by use of selective agonists and antagonists. Br J Pharmacol 86:697–704
Feniuk W, Humphrey PPA, Perren MJ (1989) The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetised dogs. Br J Pharmacol 96:83–90
Feniuk W, Humphrey PPA, Perren MJ (1989) GR43175 does not share the complex pharmacology of the ergots. Cephalalgia 9 (suppl 9): 35–39
Graham JR, Wolff HG (1938) Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry 39:737–763
Heyck H (1969) Pathogenesis of migraine. Res Clin Stud Headache 2:1–28
Humphrey PPA (1991) 5-Hydroxytryptamine and the pathophysiology of migraine. J Neurol 238 (suppl 1):S38-S44
Humphrey PPA, Feniuk W, Perren MJ, Connor HE, Oxford AW, Coates IH, Butina D (1988) GR43175 a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein. Br J Pharmacol 94:1123–1132
Humphrey PPA, Feniuk W, Perren MJ, Connor HE, Oxford AW (1989) The pharmacology of the novel 5-HT1-like receptor agonist GR43175. Cephalalgia 9 (suppl 9):63–72
Humphrey PPA, Feniuk W, Perren MJ, Skingle M, Beresford IJM, Whalley ET (1989) Further studies on the mechanism of the antimigraine action of sumatriptan. Cephalalgia 9 (suppl 10):361–362
Jansen I, Tfelt-Hansen P, Edvinsson L (1985) Comparison of the vasomotor effects of the calcium entry blocker flunarizine and nimodipine in human cerebral and temporal arteries. Cephalalgia 5 (suppl 3):206–207
Kerber CW, Newton TH (1973) The macro and microvasculature of the dura mater. Neuroradiology 6:175–179
Kimball RW, Friedman AP, Vallejo E (1960) Effect of serotonin in migraine patients. Neurology 10:107–111
Lance JW, Anthony M, Hinterberger H (1967) The control of cranial arteries by humoral mechanisms and its relation to the migraine syndrome. Headache 7:93–102
Lance JW, Lambert GA, Goadsby PJ, Zagoni A (1989) 5-Hydroxytryptamine and its putative aetiological involvement in migraine. Cephalalgia 9 (suppl 9):7–13
McCarthey BG, Peroutka SJ (1989) Comparative neuropharmacology of dihydroergotamine and sumatriptan (GR43175). Headache 29:420–422
Moskowitz MA (1984) The neurobiology of vascular head pain. Ann Neurol 16:157–168
Moskowitz MA, Buzzi MG (1991) Neuroeffector functions of sensory fibres: implications for headache mechanisms and drug actions. J Neurol 238 (suppl 1):S18-S22
Nichols FT, Mawad M, Mohr JP, Stein B, Hilal S, Michelsen WJ (1990) Focal headache during balloon inflation in the internal carotid and middle cerebral arteries. Stroke 21:555–559
Parsons AA, Whalley ET, Feniuk W, Connor HE, Humphrey PPA (1989) 5-HT1-like receptors mediate 5-hydroxytryptamine-induced contraction of human isolated basilar artery. Br J Pharmacol 96:434–440
Penfield W (1935) A contribution to the mechanism of intracranial pain. Assoc Res Neuro Ment Dis 15:399–416
Perren MJ, Feniuk W, Humphrey PPA (1989) The selective closure of feline carotid arteriovenous anastomoses (AVAs) by GR43175. Cephalalgia 9 (suppl 9):41–46
Perren MJ, Feniuk W, Humphrey PPA (1991) Vascular 5-HT1-like receptors which mediate contraction of the dog isolated saphenous vein and carotid arterial vasoconstriction in anaesthetised dogs are not of the 5-HT1A or 5-HT1D subtype. Br J Pharmacol 102:191–197
Perrin VL, Färkhilä M, Goasguen J, Doenicke A, Brand J, Tfelt-Hansen P (1989) Overview of initial clinical studies with intravenous and oral GR43175 in acute migraine. Cephalalia 9 (suppl 9):63–72
Ray BS, Wolff HG (1940) Experimental studies on headache. Pain sensitive structures of the head and their significance in headache. Arch Surg 41:813–856
Rowbotham GF, Little E (1965) New concepts on the aetiology and vascularisation of meningiomater; the mechanisms of migraine; the chemical process of the cerebrospinal fluid; and the formations of the collections of fluid in the subdural space. Br J Surg 52:21–24
Saxena PR (1972) The effects of antimigraine drugs on the vascular responses evoked by 5-hydroxytryptamine and related biogenic substances on the external carotid bed of dogs: possible pharmacological implications to their antimigraine action. Headache 12:44–54
Saxena PR (1974) Selective vasoconstriction in carotid vascular bed, by methysergide: possible relevance to its antimigraine effect. Eur J Pharmacol 27:99–105
Saxena PR (1987) The arteriovenous anastomoses and veins in migraine research. In: Blau JN (ed) Migraine — therapeutic, conceptual and research aspects. Elsevier, Amsterdam, pp 581–596
Saxena PR, Verdouw PD (1982) Redistribution by 5-hydroxytryptamine of carotid arterial blood at the expense of arteriovenous anastomotic blood flow. J Physiol (Lond) 332:501–520
Saxena PR, de Vlaam-Schluter GM (1974) Role of some biogenic substances in migraine and relevant mechanisms in antimigraine action of ergotamine. Studies in an experimental model for migraine. Headache 13:142–163
Toda N, Fujita Y (1973) Responsiveness of isolated cerebral and peripheral arteries to serotonin, norepinephrine and transmural electrical stimulation. Circ Res 33:98–103
Van Wijngaarden I, Tulp MTLM, Soudjin W (1990) The concept of selectivity in 5-HT receptor research. Eur J Pharmacol (Molec Pharmacol Sect) 188:301–312
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Feniuk, W., Humphrey, P.P.A., Perren, M.J. et al. Rationale for the use of 5-HT1-like agonists in the treatment of migraine. J Neurol 238 (Suppl 1), S57–S61 (1991). https://doi.org/10.1007/BF01642908
Issue Date:
DOI: https://doi.org/10.1007/BF01642908